Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc. (often referred to as NW Bio) is a pioneering biotechnology company headquartered in the United States, with significant operational activities in the field of cancer immunotherapy. Founded in 2001, the company has made notable strides in developing innovative therapies, particularly its lead product, DCVax®-L, which is designed to treat various types of cancer by harnessing the body’s immune system. With a focus on personalised medicine, Northwest Biotherapeutics stands out in the biopharmaceutical industry for its unique approach to dendritic cell therapy. The company has achieved key milestones, including successful clinical trials that underscore its commitment to advancing cancer treatment. As a leader in the immunotherapy sector, NW Bio continues to position itself at the forefront of cancer research, aiming to improve patient outcomes and redefine therapeutic standards.
DitchCarbon Score
How does Northwest Biotherapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Northwest Biotherapeutics, Inc.'s score of 18 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Northwest Biotherapeutics, Inc.'s reported carbon emissions
Northwest Biotherapeutics, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data for the most recent year, nor do they have specified reduction targets or climate pledges. This absence of data suggests that the company may not have established formal commitments to reduce carbon emissions or may not have disclosed such information. In the context of the biotherapeutics industry, many companies are increasingly focusing on sustainability and climate action, but specific initiatives or targets from Northwest Biotherapeutics remain unclear. As the industry evolves, it will be important for the company to consider implementing measurable climate commitments to align with broader environmental goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Northwest Biotherapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
